核因子-κB抑制剂SN50增强了靶向B细胞成熟抗原的嵌合抗原受体T细胞疗法的疗效。 - Suppr

The nuclear factor-κ B inhibitor SN50 enhances the efficacy of B-cell maturation antigen-targeted chimeric antigen receptor T-cell therapy.

作者信息

Long Jinlan, Xie Shufeng, Zhang Wenjie, Dou Weiyu, Wang Yixin, Wang Ruiheng, Liu Han, Xu Zhenshu

机构信息

Fujian Institute of Hematology, Fujian Provincial Key Laboratory of Hematology, Fujian Medical University Union Hospital, Fuzhou.

Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine and School of Life Sciences and Biotechnology, Shanghai.

出版信息

Haematologica. 2025 Jun 1;110(6):1412-1416. doi: 10.3324/haematol.2024.286689. Epub 2025 Jan 23.

DOI:10.3324/haematol.2024.286689

PMID:39844764

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12130753/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d249/12130753/041ca1fb00a3/1101412.fig1.jpg

相似文献

The nuclear factor-κ B inhibitor SN50 enhances the efficacy of B-cell maturation antigen-targeted chimeric antigen receptor T-cell therapy.核因子-κB抑制剂SN50增强了靶向B细胞成熟抗原的嵌合抗原受体T细胞疗法的疗效。

Haematologica. 2025 Jun 1;110(6):1412-1416. doi: 10.3324/haematol.2024.286689. Epub 2025 Jan 23.

[Clinical analysis of the correlation between the expression of soluble B cell maturation antigen and the efficacy of chimeric antigen receptor T cell targeting B cell maturation antigen in patients with multiple myeloma].[可溶性B细胞成熟抗原表达与嵌合抗原受体T细胞靶向B细胞成熟抗原治疗多发性骨髓瘤患者疗效的相关性临床分析]

Zhonghua Xue Ye Xue Za Zhi. 2024 Apr 14;45(4):378-382. doi: 10.3760/cma.j.issn.0253-2727.2023.01.001.

Incidence, clinical characteristics and prognosis of tumor lysis syndrome following B-cell maturation antigen-targeted chimeric antigen receptor-T cell therapy in relapsed/refractory multiple myeloma.在复发/难治性多发性骨髓瘤患者中，B 细胞成熟抗原靶向嵌合抗原受体 T 细胞治疗后肿瘤细胞溶解综合征的发生率、临床特征和预后。

Front Immunol. 2023 May 4;14:1125357. doi: 10.3389/fimmu.2023.1125357. eCollection 2023.

Therapeutic effect of topical administration of SN50, an inhibitor of nuclear factor-kappaB, in treatment of corneal alkali burns in mice.核因子-κB抑制剂SN50局部给药对小鼠角膜碱烧伤的治疗作用

Am J Pathol. 2005 May;166(5):1393-403. doi: 10.1016/s0002-9440(10)62357-7.

Cytokine profiles are associated with prolonged hematologic toxicities after B-cell maturation antigen targeted chimeric antigen receptor-T-cell therapy.细胞因子谱与 B 细胞成熟抗原靶向嵌合抗原受体 T 细胞治疗后长期血液学毒性有关。

Cytotherapy. 2023 Feb;25(2):192-201. doi: 10.1016/j.jcyt.2022.11.001. Epub 2022 Dec 7.

Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen.嵌合抗原受体修饰 T 细胞疗法在多发性骨髓瘤中的应用：超越 B 细胞成熟抗原。

Front Immunol. 2019 Jul 16;10:1613. doi: 10.3389/fimmu.2019.01613. eCollection 2019.

Chimeric Antigen Receptor T Cell Therapy for Myeloma: Where Are We Now and What Is Needed to Move Chimeric Antigen Receptor T Cells Forward to Earlier Lines of Therapy? Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.嵌合抗原受体 T 细胞疗法治疗骨髓瘤：我们现在处于什么位置，以及需要什么才能将嵌合抗原受体 T 细胞推进到更早的治疗线？美国移植和细胞治疗学会专家小组意见。

Transplant Cell Ther. 2024 Jan;30(1):17-37. doi: 10.1016/j.jtct.2023.10.022. Epub 2023 Oct 31.

Therapeutic potential of third-generation chimeric antigen receptor T cells targeting B cell maturation antigen for treating multiple myeloma.针对 B 细胞成熟抗原的第三代嵌合抗原受体 T 细胞治疗多发性骨髓瘤的治疗潜力。

Clin Exp Med. 2024 Apr 29;24(1):90. doi: 10.1007/s10238-024-01347-7.

Blocking NF-κB nuclear translocation leads to p53-related autophagy activation and cell apoptosis.阻断 NF-κB 核转位导致与 p53 相关的自噬激活和细胞凋亡。

World J Gastroenterol. 2011 Jan 28;17(4):478-87. doi: 10.3748/wjg.v17.i4.478.

Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma.嵌合抗原受体 T 细胞靶向 B 细胞成熟抗原免疫疗法对多发性骨髓瘤具有广阔的应用前景。

Ann Hematol. 2019 Apr;98(4):813-822. doi: 10.1007/s00277-018-03592-9. Epub 2019 Jan 28.

本文引用的文献

Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.西达基奥仑赛或标准护理用于来那度胺难治性多发性骨髓瘤。

N Engl J Med. 2023 Jul 27;389(4):335-347. doi: 10.1056/NEJMoa2303379. Epub 2023 Jun 5.

The BAFF-APRIL System in Cancer.癌症中的BAFF-APRIL系统

Cancers (Basel). 2023 Mar 16;15(6):1791. doi: 10.3390/cancers15061791.

Both APRIL and antibody-fragment-based CAR T cells for myeloma induce BCMA downmodulation by trogocytosis and internalization.APRIL 和基于抗体片段的骨髓瘤 CAR T 细胞均可通过 trogocytosis 和内化诱导 BCMA 下调。

J Immunother Cancer. 2022 Nov;10(11). doi: 10.1136/jitc-2022-005091.

Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2).在中国开展的一项 1 期、单臂、开放标签、多中心研究（LEGEND-2）中，评估 LCAR-B38M 治疗复发/难治性多发性骨髓瘤的 4 年随访结果。

J Hematol Oncol. 2022 Jul 6;15(1):86. doi: 10.1186/s13045-022-01301-8.

Current state and next-generation CAR-T cells in multiple myeloma.多发性骨髓瘤中当前的嵌合抗原受体 T 细胞（CAR-T）疗法和下一代 CAR-T 细胞疗法。

Blood Rev. 2022 Jul;54:100929. doi: 10.1016/j.blre.2022.100929. Epub 2022 Jan 21.

CART-Cell Therapy: Recent Advances and New Evidence in Multiple Myeloma.嵌合抗原受体T细胞（CART）疗法：多发性骨髓瘤的最新进展与新证据

Cancers (Basel). 2021 May 27;13(11):2639. doi: 10.3390/cancers13112639.

BCMA-targeted immunotherapy for multiple myeloma.BCMA 靶向免疫疗法治疗多发性骨髓瘤。

J Hematol Oncol. 2020 Sep 17;13(1):125. doi: 10.1186/s13045-020-00962-7.

SN50 attenuates alveolar hypercoagulation and fibrinolysis inhibition in acute respiratory distress syndrome mice through inhibiting NF-κB p65 translocation.SN50 通过抑制 NF-κB p65 易位减轻急性呼吸窘迫综合征小鼠的肺泡过度凝血和纤维蛋白溶解抑制。

Respir Res. 2020 May 27;21(1):130. doi: 10.1186/s12931-020-01372-6.

Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma.双表位 CAR T 靶向 B 细胞成熟抗原治疗复发/难治性多发性骨髓瘤的探索性试验。

Proc Natl Acad Sci U S A. 2019 May 7;116(19):9543-9551. doi: 10.1073/pnas.1819745116. Epub 2019 Apr 15.

The NF-κB Activating Pathways in Multiple Myeloma.多发性骨髓瘤中的NF-κB激活途径。

Biomedicines. 2018 May 16;6(2):59. doi: 10.3390/biomedicines6020059.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The nuclear factor-κ B inhibitor SN50 enhances the efficacy of B-cell maturation antigen-targeted chimeric antigen receptor T-cell therapy.

作者信息

机构信息

出版信息

相似文献

本文引用的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

本文引用的文献